je.st
news
Home
› Glenmark's Novel Monoclonal Antibody GBR 900 For Treatment Of Chronic Pain Entering Human Trials
Glenmark's Novel Monoclonal Antibody GBR 900 For Treatment Of Chronic Pain Entering Human Trials
2014-04-30 07:12:40| drugdiscoveryonline News Articles
Glenmark Pharmaceuticals S.A., a wholly owned Swiss subsidiary of Glenmark Pharmaceuticals Ltd., announced today that GBR 900, a novel monoclonal antibody is entering human trials
Tags: human
treatment
pain
entering
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||